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Cisplatin-containing salvage regimens followed by autologous hematopoietic stem cell 
(HSC) transplantation are the current standard of care for relapsed or refractory (R/R) 
lymphomas. We retrospectively analyzed efficacy and stem cell mobilizing activity of 
oxaliplatin, cytarabine, dexamethasone and rituximab (R-DHAOX) in 53 R/R diffuse 
large B cell lymphomas (DLBCL) treated in our centre (median lines 2, range 2-5; median 
age 59, range 22-79). Hematological toxicity was manageable and no patients 
experienced renal impairment. After 2 courses the overall response rate was 60% (CR 
49%, PR 11%). Median overall survival (OS) was 30.53 months (95% CI 11.5-49.55), 3-
year OS 40.5%. Twenty-two eligible patients collected HSC and transplantation was 
performed in 21/22 patients (95%), after a median of 52 days from last cycle. Our results 
suggest that in DLBCL R-DHAOX has an excellent stem cell mobilizing capability, 
response rate comparable to cisplatin-containing regimens and good toxicity profile. 
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Anthracycline-containing induction immunochemotherapy induces a high response rate 
in Diffuse Large B Cell Lymphomas (DLBCL) patients. 1-5 However, a significant 
fraction of patients is either refractory or relapses after an initial response. 6 Standard of 
care for younger patients with relapsed/refractory (R/R) DLBCL in good performance 
status is currently based on salvage chemotherapy followed by autologous stem cell 
transplantation (ASCT). 7 In this view, ideal, salvage chemotherapy regimen should be 
highly effective, tolerable and able to efficiently mobilize hemopoietic stem cells (HSC). 
The most widely used salvage regimens include platinum, such as R-DHAP (rituximab, 
cisplatin, cytarabine, dexamethasone), R-ICE (rituximab, ifosfamide, carboplatin, 
etoposide), R-GDP (rituximab, cisplatin, gemcitabine, dexamethasone) or R-ESHAP 
(Rituximab, etoposide, methylprednisone, cytarabine, and cisplatin). 8-11 
Although effective, cisplatin-containing regimens are often complicated by severe 
adverse events (SAEs), mainly renal impairment, but also mucositis and neuropathy. 
12,13 These SAEs may lead to dose reduction and delay between courses and may also 
adversely impact the feasibility of subsequent ASCT, thus reducing the chance of cure. 
14 
Therefore, platinum-derived drug oxaliplatin was specifically designed to reduce the 
cisplatin-related toxicities, especially nephrotoxicity and mucositis and oxaliplatin-
containing regimens were widely tested in solid tumours. 15 
The experience in lymphoid malignancies is still limited 16-20 and few data are available 
on the anti-tumour efficacy of oxaliplatin in R/R DLBCL, whereas no data at all have 




After a previous experience with IEV (ifosfamide, epirubicine and etoposide) as salvage 
chemotherapy, 21 we adopted a modified R-DHAP regimen including oxaliplatin instead 
of cisplatin (R-DHAOx). 22 One hundred and three consecutive R/R lymphoma patients, 
including various histologies, were treated in our Centre from 2004 to 2014. In this paper 
we focus our analysis on efficacy, toxicity and stem cell mobilizing capacity of R-
DHAOx in 53 DLBC lymphomas. 
Materials and methods 
Eligibility criteria and patient features 
We treated 53 R/R DLBCL consecutive patients aged 18 years or older who were resistant 
or had relapsed after at least one anthracycline-containing regimen, (mostly R-CHOP). 
Inclusion criteria included eligibility for intensive chemotherapy as per Institutional 
guidelines, and an ECOG <3. Informed consent was obtained according to Helsinki 
declaration. Patients were treated from October 2004 to October 2014. The retrospective 
analysis was focused on toxicity, efficacy and mobilizing activity of R-DHAOx. 
Forty-four patients (83%) were given R-DHAOx as second line therapy, 9 as third line or 
further (17%). The majority (N. 30, 56%) of patients were refractory to the previous 
regimen. Median duration of first CR for patients who received R-DHAOx for relapse 
was 11 months (range 4-32 months). Two patients had already received ASCT (4%). 
Patients’ features are summarized in Tab. I. 
Treatment Plan 
R-DHAOX consisted of dexamethasone (40 mg/die on days 1-4), oxaliplatin (130 
mg/sqm on day 1), cytarabine (2 g/sqm bid on day 2) with Rituximab 375 mg/sqm on day 
2, repeated every 21 days. All patients received prophylactic subcutaneous G-CSF 
 
 
(5µg/Kg/day) starting from day 8 until ANC >2 x 109/mmc. Patient attempting 
mobilization received G-CSF 5µg/Kg/day starting from day 8 until HSC collection. From 
2013 outpatient administration of chemotherapy was planned. 
Response assessment was performed after two courses. Patients achieving at least a 
partial remission (PR) were scheduled to receive 2 additional courses.  
All patients younger than 65 years, achieving at least PR, without severe comorbidities 
and with 0-1 ECOG performance status were considered eligible for ASCT consolidation. 
HSC mobilization and collection were attempted after the third course of R-DHAOx. 
Monitoring of circulating HSC was started on day 10 from the beginning of 
chemotherapy; HSC collection was started if a minimum of 20 CD34+ cells/uL was found 
in the peripheral blood. Plerixafor was administered if the target of circulating CD34+ 
count was not achieved at day 12. If an adequate amount of CD34+ HSC (> 2 x106/Kg) 
was collected, ASCT with conventional BEAM (carmustine, etoposide, cytarabine, 
melphalan) conditioning regimen was planned in all eligible patients achieving at least a 
PR. 2 Overall, patients received a median of 3 courses of R-DHAOx, with 95% of patients 
receiving at least 2 courses. The remaining 5% of patients showed disease progression 
after cycle 1 and therefore went off study. 
Toxicity assessment 
Renal and hepatic function were closely monitored in all patients during therapy. 
Toxicities and adverse events were defined and graded according to Common 
Terminology Criteria for Adverse Events (CTCAE) v.4.0.  
Definition of response and statistical analysis 




Complete Response (CR) required no residual FDG-PET uptake. 
Partial Response (PR) required a decrease greater than 50% of FDG-PET uptake and of 
measurable lesions at CT (in the sum of the product of the perpendicular diameters). 
Patients not fulfilling CR or PR criteria were defined as non-responders (NR). 3,4 
Patients achieving at least PR after the previous regimen (and treated in relapse) were 
defined as having a chemo-sensitive disease. 
Relapse free survival (RFS) was calculated from the time to documented CR to the 
eventual relapse. 
Progression free survival (PFS) was calculated from the beginning of R-DHAOx to 
documented disease progression or death or last follow-up, whichever occurred first. 
Overall survival (OS) was calculated from the beginning of R-DHAOx treatment until 
death due to any cause, or to the last follow up.  
Continuous variables were compared using Student’s T test or, where necessary, 
Wilcoxon’s Rank test. Dichotomous variables were compared using the Chi-square test 
or, where necessary, Fisher’s exact test.  
Survival curves were built using the Kaplan Meier method, and univariate survival 
analysis was performed using the Log-rank test. For DFS evaluation in the whole cohort 
of patients and in the subgroup analysis for patients undergoing allogeneic bone marrow 
transplantation in CR1, a landmark analysis was performed at day 90, including all 
patients alive and achieving CR after one or two induction cycles. A Cox Proportional 
Hazard Model was built for multivariate survival analysis, including only the variables 




Response and Progression Free Survival 
Overall response rate (ORR) after 2 courses was 60%, with 49% and 11% of patients 
achieving CR and PR, respectively. Notably, none of the PR patients achieved CR after 
the additional courses and none of the patients in CR showed loss of response during 
treatment. Response rate was significantly higher in patients treated for relapsed disease, 
compared to patients who showed resistance to the previous chemotherapy regimen (ORR 
79% vs 45%, respectively, p<0.01, Tab. II). Disease burden at the time of R-DHAOx 
salvage correlated with ORR (80% for stage I/II vs 45% for stage III/IV, p<0.05, Tab. II). 
Patients with a lower IPI score had an higher ORR (93% vs 49% for patients with IPI 
score lower than 3 compared to 3 or higher, respectively, p<0.03, Tab. II). The number 
of previous lines of chemotherapy and patients age at time of treatment did not impact on 
ORR. 
Multivariate regression analysis disclosed that chemosensitivity before DHAOx (i.e. 
relapsed vs resistant) was the only significant independent predictor of response (p<0.05, 
Tab. II). 
In the whole cohort, 3-year PFS was 32.6% (Fig. 1A). If analysis was restricted only to 
responding patients, median PFS was not reached, three-year PFS was 59.6% (Fig. 1B). 
Patients receiving R-DHAOx for refractory disease had a significantly shorter PFS, if 
compared to patient treated for relapse after a previous CR (3-year PFS 48.9% vs 69.8%, 
respectively, p<0.05). Receiving R-DHAOx as third or further line of salvage, age at the 
time of treatment, IPI score and staging did not impact on PFS duration (data not shown). 
 
 
Multivariate analysis showed that receiving R-DHAOx as salvage treatment after relapse 
from a previous CR rather than for refractory disease was the only independent predictor 
of longer PFS (p<0.05) 
Toxicity 
Non-hematological AEs of grade > 2 were observed in 18 patients (34%) (Table III). The 
most frequent were: neutropenic fever (11 patients), sepsis (1 patients), oral mucositis 
and other gastrointestinal events (3 patients), paraesthesia (2 patients) and atrial 
fibrillation in 1 patient. In 6 patients (11%) AEs required hospitalization. Seven patients 
(17%), treated in third or subsequent line, needed transfusion support, mainly packed red 
blood cell. No patients experienced renal impairment, grade III-IV neuropathy or 
ototoxicity of any grade. Of note, support with recombinant human erythropoiesis-
stimulating factor was planned only on clinical bases.  
HSC collection and ASCT 
After two courses of chemotherapy, 22 patients were considered eligible for ASCT 
(41,5%). Thus, HSC mobilization was planned after the third R-DHAOx cycle, following 
G-CSF stimulation. Circulating CD34+ cells peak was observed on day 14 (range: 10-16). 
After a median of 1 leukapheresis (range: 1-4), 22 out of 22 patients collected more than 
2x106 CD34+ cells/kg; 18 (81%) collected more than 4x106 CD34+ cells/kg (median 
6.4x106 CD34+ cells/kg). Only six patients (27%) collected less than 5x106 CD34+ 
cells/kg and only 1 patient required plerixafor administration to reach the minimum 
number of CD34+ cells (≥ 20/uL) to proceed to collection.  
Among 22 patients who successfully collected HSC and were at least in PR after 
chemotherapy, ASCT was eventually performed in 21 (95%), after a median of 52 days 
 
 
from last R-DHAOx (range 26-94). The patient who do not receive ASCT was in PR and 
showed disease progression before transplant.  
Survival 
After a median follow-up of 62 months, 26 patients died (49.1%), mostly because of 
disease recurrence (25/26, 96%). Median overall survival (OS) was 30.53 months (95% 
CI 11.5-49.55 months), and three-year OS was 40.5% (Fig. 2). Tab. IV reports factors 
affecting OS. Response to R-DHAOx significantly correlated with OS (3-year OS 69.7% 
and 9.4% for patient in CR or less than CR, respectively, p<0.01). Achieving a PR was 
correlated with longer OS if compared to SD or NR (3-year OS 22.2% and 9.4% for 
patient achieving PR vs SD or NR, respectively, p<0.05).  
Higher IPI score (3-year OS 67.9% and 30.8%, for patients with IPI score lower or 
equal/greater than three, respectively, p<0.03) and advanced stage disease (3-year OS 
60.9% and 28.5%, for stage I/II and III/IV, respectively, p<0.03) were both related to 
shorter survival. Neither age at the time of treatment nor chemosensitivity to previous 
chemotherapy regimens or number or previous lines of chemotherapy did impact on OS 
duration. 
In multivariate analysis, achieving a CR after R-DHAOx was the strongest, independent, 
predictor of OS duration (p<0.003). 
Discussion 
Our retrospective study shows that R-DHAOx is a well-tolerated and effective salvage 
regimen for R/R DLCBL and allows optimal HSC collection. Indeed, no severe renal, 
neurological or GI adverse events, that are usually described with DHAP, were reported 




In the attempt of avoiding cytarabine-related myelosuppression, the association of 
gemcitabine, cisplatin and dexamethasone (GDP) has been compared to DHAP in a 
randomized trial for patients with R/R lymphomas. 12-14 GDP +/- rituximab resulted in 
a similar response rate than DHAP with less myelosuppression. Progression free survival 
with GDP was comparable to that reported with other platinum-based regimens, such as 
R-ICE and R-DHAP. In our study, three-years progression-free survival (PFS) with R-
DHAOx was 32.6% in the whole cohort (59.6% in responding patients) compared to 42%, 
31% and 28% for R-DHAP, R-ICE and R-GDP, respectively. 24  
Only a few studies are available on oxaliplatin-containing salvage regimens in NHL 
patients. Lacout et al. reported, in an abstract form, on R-DHAOx administration in a 
similar cohort of patients, with comparable efficacy and safety profile. 19 
A similar regimen (Rituximab, oxaliplatin, cytosine arabinoside, dexamethasone, ROAD) 
but with different administration schedule was employed by Witzig et al., with similar 
response rate and toxicity. 18 However, the capacity of inducing HSC mobilization was 
not reported. Notably, in our study, the good safety profile allowed the administration of 
oxaliplatin-containing regimen to elderly patients (median age was 59 years and 28 were 
older than 65 years). Moreover, the short duration of drug infusion allowed to plan drug 
administration in the outpatient setting. 
More recently, alternative regimens including novel drugs have been tested. 
lenalidomide-rituximab (ReRi) has shown very good tolerability profile and good 
efficacy in R/R DLBCL not originating from germinal center. 25,26 Indeed, by 
considering its good toxicity profile and manageability, R-DHAOx regimen could be the 
backbone of a novel chemotherapy incorporating lenalidomide or other novel drugs to 
 
 
improve both response rate and feasibility. 27 
To the best of our knowledge, no data are available on the HSC mobilizing capacity of 
oxaliplatin-containing regimen in R/R lymphoma patients. Indeed, in our study, all 
patients were able to successfully collect a sufficient amount of HSC to proceed to ASCT. 
Of note, the present results are at least comparable to what is observed with conventional 
cisplatin-based salvage regimens, 28 so that R-DHAOx can be considered an effective 
alternative for R/R DLBCL and HSC mobilization. Furthermore, due to the low rate of 
renal AEs and mucositis, almost all responding patients, who successfully collected HSC, 
eventually received transplantation without significant delay. This could be a major 
advantage if compared to cisplatin-containing regimen, where extra-hematological 
toxicities may limit subsequent ASCT consolidation. 28 
In conclusion, with the limitations due to the small size of the cohort, the high response 
rate, coupled with the favourable toxicity profile and the good mobilizing capacity 
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Table I: Patient features 
  Num. % 
DLBCL PATIENTS 53 - 
Sex 
Male 35 66 
Female 18 34 
Age 
Less than 65 years 39 74 
65 years or older 14 26 
Number of 
previous lines 
One 44 83 
Two 5 10 
Three or more 4 7 
Setting 
Relapsed 24 45 
Refractory 29 55 
Stage 
I or II 19 36 
III or IV 28 64 
IPI score 
2 or less 14 26 





Table II: Analysis of Response 





ALL PATIENTS 53 6 (11) 26 (49) 32 (60) - - 
Setting 
Relapsed 24 1 (4) 18 (75) 19 (79) 
0.013 0.037 Refractory 29 5 (17) 8 (28) 13 (45) 
Number of 
previous lines 
One 44 4 (9) 22 (50) 26 (59) 
1.000 - Two or more 9 2 (22) 4 (44) 6 (66) 
Age 
Less than 65 years 39 3 (8) 19 (49) 22 (57) 
0.362 - 65 years or older 14 3 (21) 7 (50) 10 (71) 
IPI score 
2 or less 14 2 (14) 11 (79) 13 (93) 
0.004 0.053 3 or more 39 4 (10) 15 (39) 19 (49) 
Stage 
I or II 19 2 (10) 14 (70) 16 (80) 





















ALL PATIENTS 53 4 (8) 0 (0) 11 (21) 6 (11) 7 (13) 
Setting 
Relapsed 24 2 (8) 0 (0) 5 (21) 1 (4) 3 (13) 
Refractory 29 2 (7) 0 (0) 6 (21) 5 (17) 4 (8) 
Number of 
previous lines 
One 44 3 (7) 0 (0) 8 (18) 4 (9) 5(11) 
Two or more 9 1 (11) 0 (0) 3 (33) 2 (22) 2 (22) 
Age 
Less than 65 years 39 3 (8) 0 (0) 7 (18) 4 (10) 5 (13) 





Table IV: Overall Survival 









ALL PATIENTS 26 (49) 30.5 40.5 - - 
Setting 
Relapsed 10 (47) 30.5 49.4 
0.263 - Refractory 16 (53) 19.9 32.7 
Number of 
previous lines 
One 20 (46) 30.5 44.0 
0.485 - Two or more 6 (67) 20.0 27.8 
Age 
Less than 65 years 18 (46) 32.8 42.4 
0.458 - 65 years or older 8 (57) 17.5 34.7 
IPI score 
2 or less 3 (21) NR 67.9 
0.018 0.059 3 or more 23 (59) 17 30.8 
Stage 
I or II 5 (25) NR 60.9 
0.007 0.065 III or IV 21 (64) 8.6 20.5 
Response 
NR or SD 16 (76) 7.4 9.4   
PR 4 (67) 17.1 22.2 0.000 0.001 






Figure 1: Progression Free Survival (PFS) 
1A: PFS in the whole cohort 




Figure 1B: PFS in responding patients Figure 1A: PFS in all patients 
 
 
Figure 2: 3-years OS in all patients.  
 
 
